We and others have previous shown the SUMO pathway to play an important role in supporting the viability and transformation growth of Ras mutant cancer cells. The molecular mechanism underlying this process is not fully understood. PURPOSE. In this project we aim to study the following questions: 1) the mechanism by which the SUMO pathway supports cellular transformation driven by the KRAS oncogene; 2) cellular proteins that are differentially SUMOylated in Ras mutant cells; and 3) cellular pathways that are co-regulated by the Ras and the SUMO pathways. SIGNIFICANT MATERIALS AND METHODS. 1) shRNAs and CRISPR/Cas9 guides that target the SUMO ligases and SUMO pathway proteins; 2) Stable cell lines expressing SUMO proteins and ligases; 3) mass-spectrometry methodology for identifying SUMOylated proteins in cell lysates. ACCOMPLISHMENT. We discovered that KRAS mutant colorectal cancer cells exhibit altered patterns of protein SUMOylation and Ras driven transformation requires SUMO E2 ligase activity. The first part of study has been published. We are currently investigating the role of several transcription factors that are SUMO substrates for their roles in KRAS transformation.
| Ma, Chi; Kesarwala, Aparna H; Eggert, Tobias et al. (2016) NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature 531:253-7 |
| Zhang, Haibo; Luo, Ji (2016) SUMO wrestling with Ras. Small GTPases 7:39-46 |
| Yu, Bing; Swatkoski, Stephen; Holly, Alesia et al. (2015) Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9. Proc Natl Acad Sci U S A 112:E1724-33 |
| Kessler, Jessica D; Kahle, Kristopher T; Sun, Tingting et al. (2012) A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 335:348-53 |
| Weng, Meng-Tzu; Lee, Jih-Hsiang; Wei, Shu-Chen et al. (2012) Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. Proc Natl Acad Sci U S A 109:E3659-67 |
